Background
Cisplatin
cis-diaminedichloroplatinum(II), CDDP] is one of the widely used drugs to treat cancer patients. It was first discovered in 1969 [
1] and has since been used to treat a variety of malignant tumors such as lung, ovarian, head and neck, bladder and testicular cancers [
2]. Even though CDDP and other platinum complexes are not commonly used in the current therapy of breast cancers, they have recently been introduced into the clinical setting as an emerging new treatment modality [
3,
4]. The mode of action of this drug is believed to result from binding of its platinum molecule onto DNA of target cell. The incorporation of CDDP into DNA produces intrastrand and interstrand crosslink adducts [
5,
6]. The DNA-platinum adducts then prevent cells from undergoing DNA replication, prevent efficient RNA transcription and disrupting cell cycle which eventually lead them to apoptosis [
7,
8].
Survivin is usually found at low level in normal cells but it is highly expressed in most tumors [
9]. High survivin expressions in cancer cells correlated to poor prognosis, decreased apoptosis, and increased resistance to CDDP [
10,
11]. As a bifunctional protein, survivin, like other members of inhibitor of apoptosis proteins (IAPs), suppresses apoptosis by binding to caspase-3, 7 and 9 [
12]. Besides that, previous reports suggested that survivin played major roles in cell division where it was dominantly induced during G2/M phase to assist mitosis and cytokinesis [
13].
Recently, several alternative treatment modalities have been explored to overcome the drug resistance problems, and virotherapy has emerged as a promising approach. The idea of employing virus in cancer treatment arose in the early 1960s. Since then, several groups of DNA and RNA viruses with oncolytic properties have been identified including Newcastle Disease Virus (NDV). NDV was first discovered in Newcastle upon Tyne in 1927 and it causes a highly contagious disease affecting birds and poultry [
14]. The use of NDV in treating cancer was first reported by Cassel and Garret in 1965 [
15] and since then, the interest in using NDV as anti-neoplastic treatment has expanded steadily. NDV strain AF2240 was first isolated in the 1960s from a field outbreak in Malaysia and it was reported to cause high mortality and morbility in poultry. A study done by Othman et al. [
16] showed that NDV strain AF2240 has the ability to infect MCF7 cell line resulting in apoptosis. However, the activity of NDV AF2240 on cisplatin-resistant MCF7 cell line has not been reported. Thus, in this study, we investigated the oncolytic effect of this NDV strain on cisplatin-resistant MCF7 cancer cells.
Discussion
Cisplatin is one of the most potent and widely employed drugs in cancer treatment. However, development of resistance is a major issue in its effectiveness. Despite considerable advances in this field, the mechanism of resistance development and maintenance is still not fully understood. Alternative therapies including the use of oncolytic viruses are being studied. Recently, it was shown that a local isolate of NDV, AF2240, was able to induce high level of apoptosis in several cancer cell lines [
23,
24]. To investigate whether this virus is also oncolytic in cisplatin-resistant cancer cells, we studied its infectivity in MCF7 cell line versus cisplatin-resistant MCF7-CR.
To investigate the oncolytic effects of NDV-AF2240 on cisplatin-resistant cancer cells, we generated our own sub-cell line from breast cancer cell, MCF7. Repeated exposure of cisplatin to MCF7 resulted in a generation of a 1.3-fold increased in CDDP-resistance sub-cell line, MCF7-CR. This cell line displayed similar morphological changes to other cisplatin-resistant MCF7 cells [
25]. Similar to these findings, our MCF7-CR also showed higher nucleus to cytoplasm ratio, and they attached stronger to flask surfaces. Following NDV infection, these cells were found to be susceptible to NDV oncolytic activity. This finding is in agreement with recent reports which showed an induction of apoptosis in chemoresistant cancer cells [
26,
27] using NDV-HUJ and NDV-FMW strains, respectively.
In this study, we showed that NDV AF2240 killed almost 50% of both MCF7 and MCF7-CR cell lines during the first 12 hpi. From this time point onwards, the infected MCF7 cells continued to show an exponential reduction in viability suggesting their continued susceptibility to NDV-induced killing. The MCF7-CR, however, showed no significant reduction in their viability beginning from 12 until 24 hpi. The cells which were killed during the first 12 hpi in both MCF7 and MCF7-CR perhaps represent a 'rapidly cycling' pool of cells [
28]. It was shown that rapidly proliferating cells were more susceptible to vesicular stomatitis virus (VSV)-induced oncolysis [
29]. In the present study, the drastic reduction in cell viability in both infected MCF7 and MCF7-CR after 12 hpi was strongly suggestive of the involvement of cell cycle phases in the infectivity and cytotoxicity of NDV. Virus internalization was previously shown to be affected by these phases [
30]. In addition, cisplatin resistance caused changes in cell cycle regulatory proteins which affect their way of responding to the drug [
31]. These changes perhaps allow this subpopulation of MCF7-CR to respond differently to NDV infection as well. Even though this has to be examined further, especially in the context of chemoresistant cancer cells, our results showed that certain subpopulations of CDDP-resistant cells have different degrees of susceptibility to NDV.
After 12 hpi, the surviving cells in MCF7-CR became more resistant towards NDV killing compared to MCF7. When we measured the level of viral proteins inside the cells, we found that this reduced cytotocixity in MCF7-CR after 12 hpi was associated with increased NDV protein level in the cells. Viruses are known to interfere with cell cycle regulation in order to subvert host-cell function to favor viral protein translation [
26]. Even though development of cisplatin-resistance is multifactorial [
7,
10], these changes will undoubtedly affect the way cells respond to viral infection. One of the proposed mechanisms of cisplatin resistance development involved apoptosis inhibitor proteins (IAPs) such as survivin. Survivin expression is known to be influenced by viruses to cause cell cycle aberration in infected cells in order to increase viral protein expression [
32,
33]. Its expression was also increased during viral infections to facilitate virus production [
22]. In this study we showed that a reduced susceptibility of MCF7-CR to NDV cytotoxicity after 12 hpi was associated with a stabilization of survivin in the cells. As the infection progressed, the survivin level became reduced which directly correlated with reduced cell viability.
The mechanism as to how NDV regulates survivin is still not completely understood. Nonetheless Zhu et al., showed that upregulation of survivin during virus infection led to a prolonged cell viability which may assist virus production [
18]. In the present study, the stabilization of survivin in MCF7-CR beginning from 12 hpi might have led to their prolonged survival which allowed for increased viral protein production and viral progeny secretion. In hepatitis-B virus infection, a viral protein was shown to interact with host protein complex, affecting caspase activation in a survivin-dependent manner [
19]. We observed that stabilization of survivin in MCF7-CR beginning at 12 hpi was associated with an intracellular accumulation of NDV proteins. This concomitant event may have implications in the observed cellular responses to NDV infection after 12 hpi. Based on this observation, it is tempting to speculate the involvement of viral protein(s) in the stabilization of survivin, reduction of NDV-induced cell killing and increase viral progeny secretion. We are currently investigating this possibility.
Cisplatin resistant cells have been shown to express higher survivin than their cisplatin-sensitive parents [
34]. The increase in survivin rendered them less susceptible to apoptosis. These inherent properties of cisplatin-resistant cells may make them more susceptible to NDV AF2240 infectivity and viral replication. NDV-LaSota strain was shown to be more susceptible to apoptosis-resistant cells [
35]. In addition, NDV-HUJ was also shown to be more infectious towards cancer cells expressing the livin protein, which is another family member of the IAPs [
26]. Therefore it is likely that the increase in the intracellular viral protein and virus progeny production in MCF7-CR at 24 hpi was associated with stabilization of survivin level in the cells beginning at 12 hpi. This suggests that survivin in one of the main protein involved in the infectivity and oncolytic activity of NDV. Taken together, our findings suggest that survivin can be a potential target molecule to improve the efficacy of NDV as anti-cancer agents.
Methods
Establishment of cisplatin-resistant MCF-7 cell line
Estrogen-dependent MCF7 cells were obtained from the ATCC (HTB-22) and maintained in DMEM media supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic. The media, serum and antibiotic/antimycotic was purchased from PAA Laboratories: Pasching, Austria. A humidified atmosphere of 37°C and 5% CO2 was provided for cell growth. Cisplatin-resistant MCF-7 (MCF7-CR) was established from the surviving population of the parental MCF7 breast cancer cells (ATCC) following a cisplatin treatment. The treatment was performed as a seven-cyclic 24 h exposure to a final concentration of 50 mM cisplatin (Sigma-Aldrich: St. Louis, MO). Following the treatment, surviving cells were maintained for another 30 days in drug-free media. MCF-7 and MCF-7 CR cells were routinely tested for the presence of Mycoplasma to avoid contamination.
Assessment of in vitro cisplatin resistancy
Cells were plated in triplicates into 96-well tissue culture plates at a concentration of 1 × 104 cells per well in 200 μl of culture media. Cisplatin was added at a final concentration in the range of 0 – 200 μM 24 h post-plating and the cells were incubated for 24 h in 5% CO2 at 37°C. 200 μl of MTT reagent (Sigma Aldrich: St. Louis, MO; final concentration of 0.5 mg/ml in DMEM) was added to each well for 4 h incubation at 37°C, followed by addition of 100 μl of DMSO (Sigma Aldrich: St. Louis, MO). Absorbance was read at an excitation wavelength of 595 nm on an ELISA microplate reader (Model 550; BioRAD: Philadelphia, PA). Cell survival was measured as a percentage of surviving cell over untreated control cells. For both cell lines the concentration of cisplatin which resulted in 50% growth inhibition (IC50) was determined.
NDV infection of sensitive and resistant MCF-7 cell cultures
Exponentially growing MCF-7 and MCF-7 CR cells were seeded in T-75 flasks at a concentration of 3 × 106 cells per flask. The cells were then infected with NDV at 1 multiplicity of infection (MOI). After 1 h, virus-containing medium was removed and fresh growth medium was introduced into each flask. The cell culture was incubated at 37°C and 5% CO2 and harvested at different time points. Uninfected cells were used as controls.
Harvesting of cells and Immunoblot analysis
Cell pellets were harvested by lysis in 1× RIPA buffer (Pierce Biotechnology: Rockford, IL) containing protease inhibitor cocktail (Roche Diagnostics: Mannheim, Germany) and quantitated using the BCA Protein Assay kit (Pierce Biotechnology: Rockford, IL). Equal amount of protein samples were added to 6× sodium dodecyl sulfate loading buffer (1 μl loading buffer: 5 μl protein sample). The sample mixtures were boiled for 5 min before being resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) to separate the proteins on the basis of their molecular weights. After electrophoresis, the proteins were transferred to a polyvinylidene fluoride (PVDF) transfer membrane by electroblotting, and probed for survivin and NDV proteins using an anti-survivin rabbit mAb (Cell Signaling Technology: Danvers, MA), anti-actin (Sigma Aldrich: St. Louis, MO), anti-NDV and anti-NP. The blot was developed and individual bands were quantitated and normalized to the β-actin control using the ImageJ software (Wayne Rasband, NIH: Bethesda, MD).
Plaque assay
A monolayer of SW620 cells was prepared in wells of a 6-well plate. 10-fold dilutions of virus stock were prepared and 1 ml aliquots were inoculated onto the cell monolayers. The plate was incubated at 37°C and 5% CO2 for 1 h. After the incubation period, the monolayers were covered with a nutrient medium containing agar and the plate was incubated for 6 days. The monolayers were fixed with 1% formaldehyde in 0.15 N NaCl and stained with neutral red for overnight. The plate was washed and dried for plaque observation.
Statistical analysis
Statistical analyses were performed using the GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA). Student's t-test was used to evaluate the significance of differences between experimental groups. Statistically-significant differences were defined as p values less than 0.05.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NS designed the study. MJ, WC performed experiments and data analysis, NS and MJ drafted the manuscript. NS, KY revised the manuscript. All authors read and approved the final manuscript.